Table 2. Clinical outcomes of pembrolizumab monotherapy according to PD-L1 expression level.
| TPS 90–100% cohort | TPS 50–89% cohort | Total | |||
|---|---|---|---|---|---|
| Response | (N = 50) | (N = 99) | (N = 149) | p value | |
| Best response—no. (%) | |||||
| Complete response | 1 (2.0) | 1 (1.0) | 2 (1.3) | 0.49 | |
| Partial response | 28 (56.0) | 45 (45.5) | 73 (49.0) | ||
| Stable disease | 9 (18.0) | 24 (24.2) | 33 (22.2) | ||
| Progression disease | 12 (24.0) | 25 (25.3) | 37 (24.8) | ||
| Not evaluated | 0 (0.0) | 4 (4.0) | 4 (2.7) | ||
| Objective response rate—no. (%) | 29 (58.0) | 46 (46.5) | 75 (50.3) | 0.23 | |
| Disease control rate—no. (%) | 38 (76.0) | 70 (70.7) | 108 (72.5) | 0.56 | |
Complete and partial responses were assessed by the investigator according to the Response Evaluation Criteria in Solid Tumors, version 1.1. p values were calculated using Fisher's exact test. PD-L1 = programmed death ligand-1, TPS = tumor proportion score.